News
May 18, 2026
Background: Transthyretin amyloid cardiomyopathy (ATTR-CM) is an infiltrative cardiomyopathy that may occur in hereditary or wild-type forms. Although more than 150…
May 18, 2026
The association between amyloidosis and aortic valve stenosis has attracted considerable international attention. However, when researchers at Umeå University…
May 18, 2026
A new diagnostic tool developed at the University of Tennessee Health Sciences may soon make it significantly easier for physicians to detect cardiac amyloidosis, a…
May 16, 2026
AbstractObjective To assess the clinical value of dual-time-point planar imaging and SPECT/CT tomographic imaging of 99mTc-PYP in diagnosing transthyretin cardiac…
May 15, 2026
AbstractThe pathogenic transthyretin (TTR) gene variant c.182G>T, p.Trp61Leu (Trp61Leu) was previously reported once, as variant transthyretin amyloidosis (ATTRv…
May 15, 2026
OverviewAll ATTRwt patients on tafamidis 61 mg treatment will be clinically evaluated before treatment initiation and subsequently every six months for the…
May 15, 2026
BridgeBio Pharma is teaming up with BlackDoctor and HealthyWomen to highlight how the heart condition ATTR-cardiac amyloidosis (ATTR-CM) is being “systematically…
May 15, 2026
AbstractSystemic amyloid light-chain (AL) amyloidosis is characterized by the extracellular deposition of misfolded immunoglobulin light chains in tissues and is…
May 14, 2026
OverviewTransthyretin Amyloid Cardiomyopathy (ATTR-CM) is a serious and life-threatening condition where a protein called transthyretin (TTR) misfolds and builds up…
May 14, 2026
Overview The purpose of this study is to:Determine the efficacy of nucresiran in patients with hATTR-PN by evaluating the effect on neurologic impairment,…